A two-year, double-blind trial of 400 people with severe coronary calcification found that high-dose vitamin K2 plus D3 slowed the rise in artery calcium by roughly 21% versus placebo (196 vs 248 AU). Plaque imaging showed no increase in noncalcified plaque, a reassuring sign. But the supplement slowed progression and did not reverse calcium, and the study did not measure heart attacks or deaths. The participants were older (median age 71) with advanced disease, so the results may not apply to everyone. Here is what the DANCODE trial showed, what it did not, and why anyone on warfarin should talk to a doctor first.
This page is available in
